deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT02606461

Selinexor in Advanced Liposarcoma (SEAL)

A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)

Sponsor: Karyopharm Therapeutics Inc

Conditions Dedifferentiated Liposarcoma
Interventions Placebo Selinexor
Updated 35 times since 2017 Last updated: Jan 5, 2023 Started: Jan 4, 2016 Primary completion: Oct 28, 2020 Completion: Oct 26, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Dedifferentiated Liposarcoma, this trial is completed. The trial is conducted by Karyopharm Therapeutics Inc and has accumulated 35 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jul 2017 · 2 months · monthly snapshot~Jul 2017 – ~Dec 2017 · 5 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~Sep 2020 · 5 months · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Jan 2022 · 7 months · monthly snapshot~Jan 2022 – ~Feb 2023 · 13 months · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

35 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. Feb 2023 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

    Status: Active Not Recruiting → Completed

  5. Jan 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2_PHASE3

▶ Show 30 earlier versions

  1. Jun 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  2. Apr 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  3. Feb 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  4. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  5. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  6. Nov 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  7. Sep 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Recruiting → Active Not Recruiting

  8. Apr 2020 — Sep 2020 [monthly]

    Recruiting PHASE2_PHASE3

  9. Feb 2020 — Apr 2020 [monthly]

    Recruiting PHASE2_PHASE3

  10. Dec 2019 — Feb 2020 [monthly]

    Recruiting PHASE2_PHASE3

  11. Oct 2019 — Dec 2019 [monthly]

    Recruiting PHASE2_PHASE3

  12. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2_PHASE3

  13. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2_PHASE3

  14. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE2_PHASE3

  15. May 2019 — Jul 2019 [monthly]

    Recruiting PHASE2_PHASE3

  16. Mar 2019 — May 2019 [monthly]

    Recruiting PHASE2_PHASE3

  17. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE2_PHASE3

  18. Dec 2018 — Feb 2019 [monthly]

    Recruiting PHASE2_PHASE3

  19. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2_PHASE3

  20. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE2_PHASE3

  21. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2_PHASE3

  22. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2_PHASE3

  23. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2_PHASE3

  24. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE2_PHASE3

  25. Jan 2018 — Mar 2018 [monthly]

    Recruiting PHASE2_PHASE3

  26. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE2_PHASE3

  27. Jul 2017 — Dec 2017 [monthly]

    Recruiting PHASE2_PHASE3

  28. May 2017 — Jul 2017 [monthly]

    Recruiting PHASE2_PHASE3

  29. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE2_PHASE3

  30. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Karyopharm Therapeutics Inc
Data source: Karyopharm Therapeutics Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Badalona, Spain , Baltimore, United States , Barcelona, Spain , Beersheba, Israel , Berlin, Germany , Bordeaux, France , Boston, United States , Brussels, Belgium , Cambridge, United Kingdom and 52 more locations